Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner Teva choosing to end their relationship with Mesoblast on a stem cell heart disease trial. Mesoblast spun this as something good that they regained the rights from Teva, but investors …Read More
Health News Review
Over at RetractionWatch, their team does a great job following retractions of science papers. Sadly, the number of published manuscript retractions gives them more than enough material to post several times a day. There’s another phenomenon going on that I think might warrant their increased attention: the possibly rising number of retractions or corrections of science press releases (PR). Gary Schwitzer, over at Health News Review, is reviewing science PRs, which is really interesting reading. I highly recommend that you check it out. While recent data …Read More